medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2013, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2013; 29 (4)

Clinical and laboratory characterization of multiple myeloma at the Institute of Hematology and Immunology

Ramón RLG, Rivera-Keeling C, Arencibia-Núñez A, Avila-Cabrera OM, Izquierdo-Cano L, Espinosa-Estrada E, González-Pinedo L, Quintero-Sierra Y, Gutiérrez-Díaz A, Hernández-Padrón C

Language: Spanish
References: 45
Page:
PDF size: 246.65 Kb.


ABSTRACT

Introduction: multiple myeloma is a disease of worldwide distribution with higher incidence in regions of Europe and America.
Objectives: we describe the demographic characteristics of the patients with this disease, the clinical and laboratory parameters, event-free survival and overall survival and prognostic factors.
Method: a retrospective study was made which included 88 patients diagnosed with multiple myeloma treated at the Adult Service in the Institute of Hematology and Immunology from 2000 to 2010.
Results: mean age was 60,7 years and the disease was more frequent in males and Caucasian patients. Bone pain, fatigue and pallor were the main findings early in the disease. Anemia, erythrocyte sedimentation rate, high levels of creatinine, hypoalbuminemia and hypergammaglobulinemia were the most striking laboratory findings at diagnosis. Overall survival was 5,2 years and the event-free survival was 3,3 years. Patients who did not respond to the first induction scheme had a shorter survival (p ‹ 0,01), as well as patients with a baseline hemoglobin below 8 g/dL (p = 0,043) and a lower albumin 30 g/L (p = 0,035).
Conclusion: the characteristics of this group of patients did not differ from the findings of other authors.


REFERENCES

  1. Bence Jones H. On a New Substance Occurring in the Urine of a Patient with Mollities Ossium. Phil Trans R Soc Lond.1848; 138: 55-62.

  2. Kyle RA. Multiple Myeloma. Review of 869 cases. Mayo Clin Proc. 1975; 50: 29-35.

  3. Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal protein in Minnesota Community with cluster of multiple myeloma. Blood. 1972; 40: 719-26.

  4. Talerman A. Clinico-pathological study of multiple myeloma in Jamaica. Br J Cancer. 1969; 23: 285-89.

  5. Kyle RA, Nobrega FT, Kurland LT. Multiple Myeloma in Olmstead County, Minnesota. Blood. 1969; 33: 739-44.

  6. Waterhouse JA, Muir C. Cancer Incidence in Five Continents, vol 3 (IARC publ No 42) Lyon, France, International Agency for Research on Cancer, 1976. pp 142.

  7. Riedel A, Pottern LM, Blattner WA. Epidemiology of Multiple Myeloma. In: Wiernick PH, Canellos GP, Kyle RA. Neoplastic Diseases of the Blood. 2nd ed, New York:Churchill Livingstone; 1991. p. 347.

  8. Kyle RA. Gammapatías monoclonales de significado oscuro. Historia natural de 241 casos. Am J Med. 1975; 7: 375-80.

  9. Ramón L, Agramonte O, Hernández C, Espinosa E, Losada R, Cabrera O et al. Mieloma múltiple y embarazo: Primer reporte de caso en Cuba. Rev Cubana Hematol Inmunol Hemoter. 2010; 26(1): 70-5.

  10. Kyle RA, Gertz MA, Mitzig TE. Review of 1027 patients with newly diagnosed multiple mieloma. Mayo Clin Proc. 2003; 78: 21-33.

  11. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report for the International Myeloma Working Group. Br J Haematol. 2003; 121: 749-57.

  12. Kyle RA, Greipp PR. Multiple Myeloma and other plasma cell disorders. In Blood and blood forming organs. Philadelphia: WB Saunders Co. 1991.p. 593.

  13. Singhal S, Mehta J, Desikan R. Anti-tumour activity of thalidomide in refractory multiple myeloma. N Eng J Med. 1999; 341:1565–71

  14. Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer. 2006; 42: 1612-22.

  15. Ramón L, Hernández CR, Buchillón RJ, Palsencia A, Agramonte O, Hernández P. Empleo de la Talidomida en un paciente con mieloma múltiple refractario. Rev Cubana Hematol Inmunol Hemoter. 2002;18 (3): 61-3.

  16. Rajkumar SV. Thalidomide in Multiple Myeloma. Oncology. 2000; 13: 11-6

  17. Kumar SK, Rajkumar SV, Dispenzieri A. Survival improved in multiple mieloma and impact of novel herapies. Blood.2007; 111: 2516-20.

  18. Mateos MV, San Miguel JF. Bortezomib in Multiple Myeloma. Best Prac Res Clin Haematol. 2007; 20: 701-5.

  19. Kyle RA. Henry Bence Jones-physician, chemist, scientist and biographer: a man for all seasons. Br J Haematol. 2001; 115:13-18.

  20. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975; 50: 29-40.

  21. Howe HL. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001; 93: 824–42.

  22. Bladé J. De la gammapatía monoclonal de significado incierto al mieloma múltiple. Haematologica/edición española. 2011; 96: 51-7.

  23. Adegoke OJ. Is sickling trait associated with an increased risk for multiple myeloma? Medical Hypotheses. 2003; 60: 607–10.

  24. Schultz WH, Ware RE. Malignancy in patients with sickle cell disease. Am J Hematol. 2003; 74:249–53.

  25. Dispenzieri A, Kyle RA. Multiple myeloma: clinical features and indications for therapy. Best Prac Res Clin Haematol. 2005; 18: 553-68.

  26. Albarracin F, Fonseca R. Plasma cell leukemia. Blood Rev. 2011; 25: 107-12.

  27. Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults. Br Med J (Clin Res Ed) 1984; 288: 1411–6.

  28. Cavo M. Prognostic values of bone marrow plasma cell infiltration in stage I multiple myeloma. Br J Haematol. 1983; 55: 683–90.

  29. Rajkumar SV. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol. 2001; 68: 269–75.

  30. Pasqualetti P. Prognostic factors in multiple myeloma: selection using Cox’s proportional hazard model. Biomed Pharmacother. 1996; 50: 29–35.

  31. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009; 23: 435-41.

  32. Garcia-Sanz R, Alegre A, Capote FJ, Hernandez JM, Rosinol L, Rubia JL, et al. Guidelines for the use of bisphosphonates in multiple myeloma: recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group. Med Clin (Barc). 2010; 134: 268-78.

  33. Wu P, Davies F, Boyd K. The impact of extramedullary disease at presentation in the outcome of myeloma. Leuk Lymphoma. 2009; 50: 230-5.

  34. Varettoni M, Corso A, Pica G. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2009; 21: 325-30.

  35. Garrido P, Coloma A, Bocardo G, Jiménez M, Herranz LM, Arellano R, et al. Plasmocitoma testicular bilateral secundario. Aportación de un caso y revisión de la literatura. Actas Urol Esp. 2008; 3210:1039-42.

  36. Fassas AB, Ward S, Muwalla F. Myeloma of the central nervous system: strong association with unfavourable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma. 2004; 45: 291-300.

  37. Blade J, Rosiñol L. Renal, hematologic and infectious complications in multiple myeloma. Best Prac Res Clin Haematol. 2005; 18: 635–52.

  38. Lahuerta JJ, Rosiñol L. Mieloma múltiple: complicaciones y formas especiales. Haematologica/edición española.2011; 96: 287-06.

  39. Hall CG, Abraham GN. Size, shape, and hydration of a selfassociating human IgG myeloma protein: axial asymmetry as a contributing factor in serum hyperviscosity. Arch Biochem Biophys. 1984; 233:330–7.

  40. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012; 87:79–88.

  41. San-Miguel JF, Mateos MV. Can multiple myeloma become a curable disease? Haematologica. 2011; 96: 1248-56.

  42. Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic transplantation for multiple myeloma. J Clin Oncol. 2010; 28:4521-30.

  43. Giralt S. Stem Cell Transplantation for Multiple Myeloma: Current and Future Status. Hematology. 2011; 98: 191-6.

  44. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J ,Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011; 118: 4519-29.

  45. San Miguel JF, García-Sanz R. Prognostic features of multiple myeloma. Best Prac Res Clin Haematol.2005; 18: 569-83.




2020     |     www.medigraphic.com